# Efficacy and Safety of AJU-A51 in Type 2 Diabetes Mellitus Patients

> **NCT06329674** · PHASE3 · COMPLETED · sponsor: **AJU Pharm Co., Ltd.** · enrollment: 235 (actual)

## Conditions studied

- Type2 Diabetes

## Interventions

- **DRUG:** AJU-A51
- **DRUG:** A51R2
- **DRUG:** A51R3
- **DRUG:** AJU-A51 Placebo
- **DRUG:** A51R2 Placebo

## Key facts

- **NCT ID:** NCT06329674
- **Lead sponsor:** AJU Pharm Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-27
- **Primary completion:** 2022-12-01
- **Final completion:** 2023-06-13
- **Target enrollment:** 235 (ACTUAL)
- **Last updated:** 2024-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06329674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06329674, "Efficacy and Safety of AJU-A51 in Type 2 Diabetes Mellitus Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06329674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*